New hope for Tough-to-Treat lung cancer: experimental combo targets brain tumors too
NCT ID NCT07362940
Summary
This study is testing a new two-drug combination (GEN-725 plus Dositinib) for people with advanced lung cancer that has a specific genetic change (EGFR mutation). It aims to see if the treatment is safe and if it can shrink tumors, including those that have spread to the brain. The trial will enroll about 110 adults whose cancer has progressed after other treatments or who are new to this type of therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, China
-
Cancer Hospital Affiliated to Shandong First Medical University (Shandong Cancer Hospital, Shandong cancer prevention and treatment institute)
NOT_YET_RECRUITINGJinan, China
-
Henan Cancer Hospital
NOT_YET_RECRUITINGZhengzhou, China
-
Hunan Cancer Hospital
NOT_YET_RECRUITINGChangsha, China
-
The First Affiliated Hospital of Xiamen University
NOT_YET_RECRUITINGXiamen, China
Conditions
Explore the condition pages connected to this study.